Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.Myriad Genetics ( MYGN) pushed the Diversified Services industry higher today making it today's featured diversified services winner. The industry as a whole was unchanged today. By the end of trading, Myriad Genetics rose $0.78 (3.1%) to $25.86 on heavy volume. Throughout the day, 2,731,075 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 1,730,800 shares. The stock ranged in a price between $25.10-$26.50 after having opened the day at $26.02 as compared to the previous trading day's close of $25.08. Other companies within the Diversified Services industry that increased today were: Command Security Corporation ( MOC), up 11.0%, Luna Innovations ( LUNA), up 9.0%, General Finance Corporation ( GFN), up 8.4% and DLH Holdings ( DLHC), up 7.5%.
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.0 billion and is part of the services sector. Shares are down 10.5% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Myriad Genetics a buy, 1 analyst rates it a sell, and 8 rate it a hold. TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.